Related Experiment Videos
Treatment of Parkinson's disease with proglumide, a CCK antagonist
R Piolti1, I Appollonio, E Cocco
1Department of Neurology, School of Medicine, University of Milan, Italy.
Neurology
|May 1, 1991
Abstract:
Proglumide, a cholecystokinin antagonist, did not improve Parkinson's disease in a preliminary drug treatment trial.
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Home-based, computer-assisted cognitive rehabilitation for attention in pediatric onset multiple sclerosis: a randomized, multicenter pilot study.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2024
Spinal cord MRI activity in multiple sclerosis: Predictive value for relapses and impact on treatment decisions.
Journal of the neurological sciences·2024
Pregnancy effect on disease activity in women with multiple sclerosis treated with cladribine.
Journal of neurology·2024
Multidimensional frailty and its association with quality of life and disability: A cross-sectional study in people with multiple sclerosis.
Multiple sclerosis and related disorders·2023
An overall view of the most common experimental models for multiple sclerosis.
Neurobiology of disease·2023
Leukocyte telomere length in women with multiple sclerosis: Comparison with healthy women during pregnancy and puerperium.
Journal of neuroimmunology·2023
Trends and Gender Disparities in Medical Narcotics Utilization in South Korea: A Nationwide Population-Based Study, 2019-2023.
Pharmacoepidemiology and drug safety·2026
GLP-1 Receptor Agonists in Dermatology: Prescribing Frameworks, Access, and the Emerging Pipeline.
Clinics in dermatology·2026
When Buprenorphine Was Not Enough: Methadone Treatment of Tianeptine Use Disorder.
Journal of addiction medicine·2026
Open-air drug markets and opioid-related overdose deaths.
Health & place·2026
Suzetrigine Is Not Expected to Have Clinically Relevant DDIs with Apixaban and Rivaroxaban Based on PBPK Modeling.
Journal of clinical pharmacology·2026
Bibliometric analysis of diversity, equity, and inclusion in U.S. pharmacy literature, 2000-2024.
Journal of the American Pharmacists Association : JAPhA·2026